CureVac N.V [CVAC] stock is trading at $2.65, up 2.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CVAC shares have lost -4.33% over the last week, with a monthly amount drifted -12.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CureVac N.V [NASDAQ: CVAC] stock has seen the most recent analyst activity on April 25, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $4 from $12. Previously, SVB Securities started tracking the stock with Outperform rating on June 08, 2023, and set its price target to $13. On January 19, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $18 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $21 on January 09, 2023. BofA Securities downgraded its rating to a Underperform and reduced its price target to $20 on January 21, 2022. JMP Securities started tracking with a Mkt Outperform rating for this stock on January 18, 2022, and assigned it a price target of $52. In a note dated October 22, 2021, Deutsche Bank initiated an Hold rating and provided a target price of $35 on this stock.
CureVac N.V [CVAC] stock has fluctuated between $2.21 and $5.28 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. CureVac N.V [NASDAQ: CVAC] shares were valued at $2.65 at the most recent close of the market. An investor can expect a potential return of 994.34% based on the average CVAC price forecast.
Analyzing the CVAC fundamentals
CureVac N.V [NASDAQ:CVAC] reported sales of 595.81M for the trailing twelve months, which represents a growth of 2925.93%. Gross Profit Margin for this corporation currently stands at 0.7% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.21 and Total Capital is 0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.50 points at the first support level, and at 2.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.78, and for the 2nd resistance point, it is at 2.90.
Ratios To Look Out For
For context, CureVac N.V’s Current Ratio is 6.20. Also, the Quick Ratio is 6.19, while the Cash Ratio stands at 5.84. Considering the valuation of this stock, the price to sales ratio is 1.00, the price to book ratio is 0.74 and price to earnings (TTM) ratio is 4.88.
Transactions by insiders
Recent insider trading involved Myriam Mendila, affiliate, that happened on Jan 07 ’25 when 17839.0 shares were purchased. affiliate, Pierre Kemula completed a deal on Jan 07 ’25 to buy 51523.0 shares. Meanwhile, affiliate Alexander Zehnder bought 26104.0 shares on Jan 07 ’25.
